Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

4 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
5 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.

Lutein supplementation may improve vision in NPDR patients

16 May 2017
Severe proliferative diabetic retinopathy Photo courtesy of Prof Tien Y Wong, Singapore National Eye Centre

Supplementation with lutein has the potential to enhance visual function in patients with nonproliferative diabetic retinopathy (NPDR), especially for contrast sensitivity (CS) at low spatial frequency, a new study has found.

To determine whether supplementation with lutein would improve visual function, researchers randomly assigned 31 patients with NPDR to 10 mg/day of lutein or identical placebo for 36 weeks. They measured visual performance indices, as well as visual acuity (VA), CS and glare sensitivity (GS) at four different spatial frequency at baseline, week 18 and 36.

Patients in the lutein group had a slight improvement in VA at week 36. There was a significant association between the changes in VA and the corresponding baseline values in treatment group (r=‒0.53; p=0.04).

At week 36, the lutein group also increased CS at four spatial frequencies, and the improvement obtained was statistically significant at 3 cycles/degree (p=0.02). The changes in CS at 3 cycles/degree for the lutein group was marginally significantly higher than those for the placebo group (p=0.09).

A slight increase in GS was also observed in the lutein group up to week 36. However, there were no significant changes seen in any cycles/degree over time.

Further large, long-term randomized controlled trials are warranted to determine the possibility that lutein supplementation could be used as an adjunct therapy to prevent vision loss and inhibit progression of retinopathy in diabetic patients, which may be important for establishing preventive and treatment approaches for this disease, researchers said.

“Diabetic retinopathy is retinal damage, specifically to blood vessels in the retina, caused by complications of diabetic mellitus,” according to researchers. [Lancet 2010;376:124-36]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

4 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
5 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.